Swedish biopharma company BioArctic AB has announced that it will utilize the proprietary epitope mapping technology, Seqitope™, from AAX Biotech.
AAX Biotech is a biotech company that specializes in innovative technologies for improving antibody-based medicines. The company’s two pioneering technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market. This marks a significant milestone for AAX Biotech, highlighting the company’s role in advancing research with its Seqitope™ technology—a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
“Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases which affect millions of persons worldwide,” says Maria L. Knudsen, CEO of AAX Biotech. “We are fully committed to this challenging project and are eager to apply our technology to support BioArctic.”
For more information about this partnership between BioArctic AB and AAX Biotech AB, please contact Maria Lisa Knudsen at [maria.knudsen@aaxbiotech.com](mailto:maria.knudsen@aaxbiotech.com) or visit [www.aaxbiotech.com](http://www.aaxbiotech.com).
The Cowboys have kicked off organized team activities, but star player CeeDee Lamb is nowhere…
Iroquois Softball Celebrates Walk-Off Win in PlayoffsThe Erie Times-News sports department recognized notable performances by…
Southern Team Automotive Group recently opened a new Hyundai sales and service center in Roanoke…
As the world continues to generate massive amounts of data, the demand for next-generation technologies…
Austin FC is looking to say goodbye to Emiliano Rigoni, their designated player from São…
In an effort to boost domestic production and increase clean energy capacity, the Biden administration…